NCT02990390

Brief Summary

RSA is a multifactorial disorder resulting from genetic factors, anatomic factors, autoimmune disorders, endocrine dysfunction, thrombophilia, life style factors, and maternal infections. However, the underlying causes remain undetermined in up to 50% of cases. In this clinical cohort study, we intended to get an epidemiological evidence for patients with recurrent spontaneous abortion associated with thrombophilla.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
45,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

November 27, 2016

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 13, 2016

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2019

Completed
Last Updated

December 14, 2016

Status Verified

November 1, 2016

Enrollment Period

2.9 years

First QC Date

November 27, 2016

Last Update Submit

December 13, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • D-Dimer

    through study completion, an average of 3 year

Secondary Outcomes (3)

  • BMI in kg/m^2

    through study completion, an average of 3 year

  • platelet aggregation time

    through study completion, an average of 3 year

  • anticardiolipin antibody

    through study completion, an average of 3 year

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Woman who had their Second miscarriage before 12(th) week of gestation.

You may qualify if:

  • Woman who had 2 miscarriages before 12(th) week of gestation.Signed consent form.

You may not qualify if:

  • having experienced severe allergies, trauma history and/or operation history within 3 months;
  • with a history of mental illness and/or family history of mental illness
  • limb disabled
  • taking medicine within one month
  • suffering major events or having mood swings
  • with a history of recurrent pregnancy loss
  • having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine)
  • chromosome aberrations in anyone of the couple.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai first Maternity and Infant health hospital, Tong Ji University

Shanghai, 200051, China

RECRUITING

Study Design

Study Type
observational
Observational Model
COHORT
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 27, 2016

First Posted

December 13, 2016

Study Start

November 1, 2016

Primary Completion

October 1, 2019

Study Completion

October 1, 2019

Last Updated

December 14, 2016

Record last verified: 2016-11

Locations